Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide in High-Risk Relapsed/Refractory Multiple Myeloma
NCT01177735Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Oct 2011
- Primary completion
- Sep 2013
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: Progression-free Survival at 1 year. Started Oct 2011; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01177735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177735.